glp-1-based therapy Oral Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Receptor Agonists as Treatments

Glucagon-like peptide-1 receptor agonists have demonstrated significant weight loss and cardiovascular benefits in both patients with and without diabetes, including a reduction in major adverse cardiovascular events

R.SorianoA.CornelyO

for sourcing insights

doi: 10.1002/jcsm.12264 122 Roman-PrezM.Bullich-VilarrubiasC.Lpez-AlmelaI.Libana-GarcaR.OlivaresM.SanzY

FASEB J 17:9193 Koh EH, Kim MS, Park JY et al (2003) Peroxisome proliferator-activated receptor (PPAR)- activation prevents diabetes in OLETF rats: comparison with PPAR- activation

Motif Neurotech , a company developing a brain pacemaker for depression, secured $18.75M in an oversubscribed Series A round led by Arboretum Ventures